- Home
- ESGL vs MOLN Comparison
ESGL vs MOLN Comparison
Compare ESGL & MOLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Company Overview
Basic Information| Metric | ESGL | MOLN |
|---|---|---|
| Founded | 1999 | 2004 |
| Country | Singapore | Switzerland |
| Employees | N/A | N/A |
| Industry | | |
| Sector | | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 169.6M | 164.2M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | ESGL | MOLN |
|---|---|---|
| Price | $3.97 | $4.17 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $3.75 |
| AVG Volume (30 Days) | ★ 9.0K | 5.3K |
| Earning Date | 03-03-2026 | 03-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $5,328,277.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $999.99 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.90 | $3.36 |
| 52 Week High | $4.32 | $5.91 |
Technical Indicators
Market Signals| Indicator | ESGL | MOLN |
|---|---|---|
| Relative Strength Index (RSI) | 45.72 | 45.23 |
| Support Level | $3.90 | $4.09 |
| Resistance Level | $3.95 | $4.31 |
| Average True Range (ATR) | 0.07 | 0.16 |
| MACD | -0.01 | -0.03 |
| Stochastic Oscillator | 85.00 | 5.13 |
Price Performance
Historical ComparisonAbout ESGL ESGL Holdings Limited
ESGL Holdings Ltd is a waste management, treatment, and recycling company involved in the collection and recycling of hazardous and non-hazardous industrial waste from customers such as pharmaceutical, semiconductor, petrochemical, and electroplating companies.
About MOLN Molecular Partners AG
Molecular Partners AG is a clinical stage biopharmaceutical company. The Company has programs in various stages of pre-clinical and clinical development, with oncology as its main focus. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company's product pipeline is organized principally through three areas: Ophthalmology, including the creation of therapies for retinal diseases like wet age-related macular degeneration and diabetic macular edema; the Oncology pipeline comprises DARPin candidates with novel modes of action, including multi-DARPin compounds; and Immuno-oncology for anticancer treatment.